| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 20 | 2024 | 1294 | 3.150 |
Why?
|
| Intermittent Claudication | 6 | 2023 | 306 | 2.680 |
Why?
|
| Stents | 22 | 2021 | 3299 | 1.890 |
Why?
|
| Lower Extremity | 13 | 2024 | 1184 | 1.750 |
Why?
|
| Angioplasty, Balloon, Coronary | 14 | 2020 | 1879 | 1.540 |
Why?
|
| Coronary Artery Disease | 31 | 2024 | 6591 | 1.470 |
Why?
|
| Drug-Eluting Stents | 6 | 2023 | 757 | 1.410 |
Why?
|
| Femoral Artery | 7 | 2023 | 831 | 1.380 |
Why?
|
| Ticlopidine | 5 | 2016 | 894 | 1.370 |
Why?
|
| Ischemia | 8 | 2023 | 1874 | 1.360 |
Why?
|
| Heptanoic Acids | 9 | 2009 | 347 | 1.300 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2023 | 3159 | 1.230 |
Why?
|
| Acute Coronary Syndrome | 7 | 2023 | 2355 | 1.210 |
Why?
|
| Endovascular Procedures | 6 | 2023 | 2062 | 1.170 |
Why?
|
| Endothelium, Vascular | 30 | 2014 | 4419 | 1.040 |
Why?
|
| Coronary Disease | 20 | 2008 | 5996 | 1.030 |
Why?
|
| Ultrasonography, Interventional | 12 | 2019 | 1486 | 1.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2012 | 3307 | 1.010 |
Why?
|
| Angioplasty, Balloon | 7 | 2020 | 610 | 0.960 |
Why?
|
| Pyrroles | 9 | 2009 | 1131 | 0.960 |
Why?
|
| Leg | 3 | 2016 | 1090 | 0.950 |
Why?
|
| Cardiology | 9 | 2024 | 1703 | 0.910 |
Why?
|
| Angioplasty | 4 | 2020 | 361 | 0.870 |
Why?
|
| Angina Pectoris | 6 | 2009 | 970 | 0.840 |
Why?
|
| Myocardial Infarction | 24 | 2024 | 11829 | 0.810 |
Why?
|
| C-Reactive Protein | 9 | 2013 | 3805 | 0.740 |
Why?
|
| Vasodilation | 10 | 2019 | 961 | 0.710 |
Why?
|
| Anticholesteremic Agents | 9 | 2009 | 985 | 0.680 |
Why?
|
| Coronary Artery Bypass | 8 | 2024 | 2265 | 0.680 |
Why?
|
| Angina, Unstable | 5 | 2004 | 926 | 0.670 |
Why?
|
| Metals | 3 | 2015 | 726 | 0.660 |
Why?
|
| Arteriosclerosis | 14 | 2004 | 1053 | 0.660 |
Why?
|
| Persian Gulf Syndrome | 1 | 2019 | 46 | 0.640 |
Why?
|
| Vascular Patency | 6 | 2023 | 901 | 0.630 |
Why?
|
| Vascular Resistance | 4 | 2019 | 926 | 0.630 |
Why?
|
| Coronary Vasospasm | 2 | 2014 | 83 | 0.620 |
Why?
|
| Veterans | 2 | 2023 | 2570 | 0.610 |
Why?
|
| Coronary Stenosis | 4 | 2018 | 816 | 0.610 |
Why?
|
| Popliteal Artery | 3 | 2023 | 312 | 0.560 |
Why?
|
| American Heart Association | 5 | 2024 | 1070 | 0.560 |
Why?
|
| Withholding Treatment | 1 | 2021 | 607 | 0.560 |
Why?
|
| Coronary Vessels | 13 | 2014 | 3105 | 0.550 |
Why?
|
| Coronary Angiography | 16 | 2014 | 4543 | 0.540 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2011 | 755 | 0.530 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2016 | 877 | 0.490 |
Why?
|
| Cholesterol, LDL | 13 | 2009 | 2407 | 0.490 |
Why?
|
| Microvessels | 1 | 2019 | 570 | 0.480 |
Why?
|
| Licensure, Medical | 1 | 2014 | 67 | 0.470 |
Why?
|
| Acetylcholine | 4 | 2014 | 629 | 0.450 |
Why?
|
| Vascular Surgical Procedures | 4 | 2017 | 1458 | 0.450 |
Why?
|
| Treatment Outcome | 34 | 2024 | 64288 | 0.440 |
Why?
|
| Hypolipidemic Agents | 5 | 2002 | 621 | 0.440 |
Why?
|
| Atrial Fibrillation | 6 | 2024 | 5147 | 0.440 |
Why?
|
| Vitamin E | 6 | 2006 | 872 | 0.430 |
Why?
|
| Specialty Boards | 1 | 2014 | 228 | 0.420 |
Why?
|
| Myocardial Revascularization | 2 | 2011 | 841 | 0.420 |
Why?
|
| Myocardial Ischemia | 8 | 2014 | 2151 | 0.420 |
Why?
|
| Aortic Rupture | 1 | 2015 | 312 | 0.410 |
Why?
|
| Hemorrhage | 6 | 2024 | 3570 | 0.400 |
Why?
|
| Amlodipine | 1 | 2012 | 81 | 0.400 |
Why?
|
| Humans | 161 | 2024 | 752810 | 0.400 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 866 | 0.400 |
Why?
|
| Drug Therapy, Combination | 8 | 2023 | 6482 | 0.400 |
Why?
|
| Risk Factors | 41 | 2024 | 73418 | 0.390 |
Why?
|
| Drug Administration Schedule | 5 | 2021 | 4883 | 0.390 |
Why?
|
| Coronary Sinus | 1 | 2012 | 84 | 0.380 |
Why?
|
| Serum Amyloid A Protein | 3 | 2013 | 125 | 0.380 |
Why?
|
| Aspirin | 3 | 2023 | 3339 | 0.380 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2012 | 120 | 0.370 |
Why?
|
| Ascorbic Acid | 6 | 2006 | 653 | 0.370 |
Why?
|
| Septal Occluder Device | 1 | 2011 | 132 | 0.360 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 1389 | 0.360 |
Why?
|
| Blood Vessels | 1 | 2016 | 1114 | 0.360 |
Why?
|
| Coronary Thrombosis | 2 | 2020 | 485 | 0.350 |
Why?
|
| Disease Management | 4 | 2017 | 2479 | 0.350 |
Why?
|
| Enalapril | 1 | 2012 | 310 | 0.350 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 826 | 0.350 |
Why?
|
| Mastitis | 2 | 2001 | 43 | 0.350 |
Why?
|
| Foreign-Body Migration | 1 | 2011 | 218 | 0.340 |
Why?
|
| Aorta, Thoracic | 2 | 2015 | 1071 | 0.340 |
Why?
|
| Cholesterol | 8 | 1999 | 2903 | 0.340 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2009 | 20 | 0.330 |
Why?
|
| Subclavian Artery | 1 | 2009 | 129 | 0.330 |
Why?
|
| Graft Occlusion, Vascular | 4 | 2020 | 555 | 0.330 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2012 | 516 | 0.320 |
Why?
|
| Foramen Ovale, Patent | 1 | 2011 | 214 | 0.320 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1069 | 0.320 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2015 | 685 | 0.320 |
Why?
|
| Blood Flow Velocity | 5 | 2019 | 1369 | 0.320 |
Why?
|
| Embolism | 1 | 2011 | 409 | 0.310 |
Why?
|
| Limb Salvage | 3 | 2023 | 460 | 0.310 |
Why?
|
| Cause of Death | 3 | 2024 | 3685 | 0.300 |
Why?
|
| Endothelin-1 | 3 | 2009 | 301 | 0.300 |
Why?
|
| Vascular Diseases | 1 | 2016 | 1177 | 0.300 |
Why?
|
| Propensity Score | 4 | 2016 | 1872 | 0.290 |
Why?
|
| Antioxidants | 6 | 2006 | 1651 | 0.290 |
Why?
|
| Proportional Hazards Models | 9 | 2024 | 12455 | 0.290 |
Why?
|
| Prosthesis Design | 4 | 2016 | 2121 | 0.280 |
Why?
|
| Vasomotor System | 6 | 2005 | 207 | 0.280 |
Why?
|
| Male | 85 | 2024 | 355160 | 0.280 |
Why?
|
| Neovascularization, Physiologic | 1 | 2014 | 1336 | 0.270 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2009 | 288 | 0.270 |
Why?
|
| Antihypertensive Agents | 3 | 2012 | 2037 | 0.270 |
Why?
|
| Multivariate Analysis | 10 | 2016 | 12138 | 0.270 |
Why?
|
| Time Factors | 21 | 2024 | 39885 | 0.270 |
Why?
|
| Endarterectomy, Carotid | 1 | 2011 | 552 | 0.260 |
Why?
|
| Arteries | 3 | 2018 | 1117 | 0.260 |
Why?
|
| CD40 Ligand | 2 | 2004 | 489 | 0.260 |
Why?
|
| Ambulatory Care Facilities | 1 | 2011 | 917 | 0.260 |
Why?
|
| Middle Aged | 68 | 2024 | 217250 | 0.250 |
Why?
|
| Ankle Brachial Index | 2 | 2018 | 157 | 0.240 |
Why?
|
| Upper Extremity | 1 | 2009 | 648 | 0.240 |
Why?
|
| Electrocardiography | 9 | 2013 | 6379 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2017 | 10200 | 0.240 |
Why?
|
| Advisory Committees | 3 | 2017 | 780 | 0.230 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2013 | 1187 | 0.230 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 1411 | 0.230 |
Why?
|
| Carotid Stenosis | 1 | 2011 | 861 | 0.230 |
Why?
|
| Vasoconstriction | 2 | 2009 | 592 | 0.230 |
Why?
|
| Coronary Circulation | 7 | 2009 | 1561 | 0.210 |
Why?
|
| Fibrinolytic Agents | 2 | 2023 | 2169 | 0.210 |
Why?
|
| Angioplasty, Balloon, Laser-Assisted | 1 | 2002 | 23 | 0.210 |
Why?
|
| Coronary Restenosis | 2 | 2003 | 426 | 0.210 |
Why?
|
| Lovastatin | 2 | 2002 | 115 | 0.210 |
Why?
|
| Stroke | 5 | 2024 | 9887 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 7407 | 0.210 |
Why?
|
| Aged | 48 | 2024 | 166705 | 0.210 |
Why?
|
| Nitric Oxide | 6 | 2001 | 2114 | 0.210 |
Why?
|
| Female | 71 | 2024 | 386339 | 0.200 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 1657 | 0.200 |
Why?
|
| Anticoagulants | 5 | 2024 | 4830 | 0.200 |
Why?
|
| Postoperative Care | 2 | 2021 | 1465 | 0.200 |
Why?
|
| Syndrome | 6 | 2003 | 3273 | 0.190 |
Why?
|
| Breast Feeding | 2 | 2001 | 1348 | 0.190 |
Why?
|
| Boston | 3 | 2023 | 9235 | 0.190 |
Why?
|
| Constriction, Pathologic | 4 | 2018 | 1099 | 0.190 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 2241 | 0.190 |
Why?
|
| Biomedical Research | 2 | 2016 | 3382 | 0.190 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2024 | 552 | 0.190 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 1871 | 0.180 |
Why?
|
| United States | 18 | 2024 | 71434 | 0.180 |
Why?
|
| Clinical Competence | 3 | 2014 | 4713 | 0.180 |
Why?
|
| Atherosclerosis | 4 | 2014 | 3502 | 0.180 |
Why?
|
| Diet Surveys | 2 | 1997 | 1159 | 0.180 |
Why?
|
| Renal Dialysis | 1 | 2009 | 1736 | 0.180 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2024 | 353 | 0.180 |
Why?
|
| Saphenous Vein | 2 | 2020 | 527 | 0.170 |
Why?
|
| Ambulatory Care | 1 | 2011 | 2743 | 0.170 |
Why?
|
| Lipoproteins, LDL | 6 | 2005 | 641 | 0.170 |
Why?
|
| Brachial Artery | 5 | 2004 | 368 | 0.170 |
Why?
|
| Laboratories | 3 | 2012 | 459 | 0.170 |
Why?
|
| Defibrillators, Implantable | 2 | 2024 | 1478 | 0.170 |
Why?
|
| New South Wales | 6 | 2001 | 70 | 0.170 |
Why?
|
| Fibrinogen | 2 | 1993 | 885 | 0.170 |
Why?
|
| Australia | 8 | 2013 | 1277 | 0.170 |
Why?
|
| Endpoint Determination | 2 | 2013 | 592 | 0.170 |
Why?
|
| Hospital Mortality | 3 | 2013 | 5370 | 0.160 |
Why?
|
| Secondary Prevention | 3 | 2012 | 1546 | 0.160 |
Why?
|
| Risk Assessment | 10 | 2024 | 23785 | 0.160 |
Why?
|
| Pacemaker, Artificial | 1 | 2024 | 812 | 0.160 |
Why?
|
| Emergency Treatment | 2 | 2012 | 497 | 0.150 |
Why?
|
| Hypercholesterolemia | 6 | 2003 | 1155 | 0.150 |
Why?
|
| Nitroglycerin | 5 | 2002 | 323 | 0.150 |
Why?
|
| Recurrence | 8 | 2013 | 8424 | 0.150 |
Why?
|
| Brain Ischemia | 1 | 2011 | 3128 | 0.150 |
Why?
|
| Societies, Medical | 3 | 2024 | 3834 | 0.150 |
Why?
|
| Acute Disease | 6 | 2003 | 7217 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5840 | 0.140 |
Why?
|
| Dietary Fats | 2 | 1997 | 1985 | 0.140 |
Why?
|
| Logistic Models | 5 | 2016 | 13277 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 3584 | 0.140 |
Why?
|
| Analysis of Variance | 3 | 2015 | 6245 | 0.130 |
Why?
|
| Immunodiffusion | 2 | 1993 | 151 | 0.130 |
Why?
|
| Quality of Life | 4 | 2022 | 13162 | 0.130 |
Why?
|
| Veterans Disability Claims | 1 | 2015 | 22 | 0.130 |
Why?
|
| Societies, Scientific | 1 | 2017 | 220 | 0.130 |
Why?
|
| Heart Transplantation | 6 | 2009 | 3065 | 0.130 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 1997 | 225 | 0.130 |
Why?
|
| Risk | 4 | 2009 | 9613 | 0.130 |
Why?
|
| Puerperal Disorders | 1 | 1998 | 299 | 0.130 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 39089 | 0.130 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2018 | 275 | 0.130 |
Why?
|
| Predictive Value of Tests | 10 | 2018 | 15146 | 0.130 |
Why?
|
| Retreatment | 2 | 2011 | 600 | 0.130 |
Why?
|
| Cardiovascular Diseases | 3 | 2012 | 15619 | 0.120 |
Why?
|
| Writing | 1 | 2017 | 200 | 0.120 |
Why?
|
| Nitrates | 1 | 1996 | 262 | 0.120 |
Why?
|
| Double-Blind Method | 9 | 2020 | 12322 | 0.120 |
Why?
|
| Heart Failure | 3 | 2024 | 11728 | 0.120 |
Why?
|
| Magnesium Sulfate | 1 | 1995 | 73 | 0.120 |
Why?
|
| Lipoprotein(a) | 3 | 2009 | 494 | 0.120 |
Why?
|
| Registries | 6 | 2019 | 8363 | 0.120 |
Why?
|
| Stroke Volume | 3 | 2024 | 5444 | 0.120 |
Why?
|
| Hospitals, Veterans | 1 | 2016 | 396 | 0.120 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2000 | 578 | 0.120 |
Why?
|
| Odds Ratio | 7 | 2013 | 9701 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 20350 | 0.110 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2018 | 327 | 0.110 |
Why?
|
| Retrospective Studies | 11 | 2023 | 79160 | 0.110 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 15695 | 0.110 |
Why?
|
| Inflammation | 6 | 2009 | 10692 | 0.110 |
Why?
|
| Adult | 40 | 2019 | 217168 | 0.110 |
Why?
|
| Digoxin | 1 | 1995 | 247 | 0.110 |
Why?
|
| Salicylates | 1 | 2014 | 125 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 5 | 2019 | 5481 | 0.110 |
Why?
|
| Calcinosis | 1 | 2001 | 1478 | 0.100 |
Why?
|
| Regional Blood Flow | 5 | 2009 | 1490 | 0.100 |
Why?
|
| Neopterin | 1 | 2012 | 55 | 0.100 |
Why?
|
| Apolipoproteins B | 2 | 2009 | 385 | 0.100 |
Why?
|
| Reproducibility of Results | 9 | 2019 | 19907 | 0.100 |
Why?
|
| Edetic Acid | 1 | 1992 | 280 | 0.100 |
Why?
|
| Hemodynamics | 6 | 2012 | 4173 | 0.100 |
Why?
|
| Long-Term Care | 1 | 2015 | 623 | 0.100 |
Why?
|
| Thrombosis | 4 | 2012 | 3018 | 0.090 |
Why?
|
| Atherectomy, Coronary | 2 | 2001 | 145 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2024 | 3821 | 0.090 |
Why?
|
| Exercise | 2 | 2018 | 5745 | 0.090 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 261 | 0.090 |
Why?
|
| Epoprostenol | 1 | 2012 | 249 | 0.090 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2012 | 151 | 0.090 |
Why?
|
| Apolipoproteins A | 1 | 1991 | 94 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2016 | 7899 | 0.090 |
Why?
|
| Interleukin-18 | 1 | 2012 | 249 | 0.090 |
Why?
|
| Aged, 80 and over | 14 | 2024 | 58347 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 192 | 0.090 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2010 | 64 | 0.090 |
Why?
|
| Hospitals, Teaching | 2 | 1996 | 1165 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2012 | 851 | 0.090 |
Why?
|
| Family Practice | 4 | 1998 | 507 | 0.090 |
Why?
|
| Drug Therapy | 1 | 2013 | 499 | 0.090 |
Why?
|
| Device Removal | 2 | 2011 | 635 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 3 | 2014 | 1810 | 0.080 |
Why?
|
| Receptor, Endothelin A | 3 | 2009 | 57 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 3 | 2014 | 2171 | 0.080 |
Why?
|
| Energy Intake | 1 | 1997 | 2125 | 0.080 |
Why?
|
| Angiography | 2 | 2019 | 1607 | 0.080 |
Why?
|
| Utilization Review | 1 | 1991 | 382 | 0.080 |
Why?
|
| Heart Arrest | 2 | 2013 | 1487 | 0.080 |
Why?
|
| Pulmonary Artery | 2 | 2012 | 1926 | 0.080 |
Why?
|
| Vasodilator Agents | 4 | 2014 | 973 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 632 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2013 | 689 | 0.080 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 569 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2014 | 1560 | 0.080 |
Why?
|
| Interleukin-6 | 3 | 2013 | 3196 | 0.080 |
Why?
|
| Cholesterol, HDL | 4 | 2003 | 1815 | 0.080 |
Why?
|
| Catheters | 1 | 2011 | 423 | 0.080 |
Why?
|
| Prognosis | 6 | 2024 | 29369 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 3463 | 0.080 |
Why?
|
| Blood Pressure | 4 | 2003 | 8468 | 0.080 |
Why?
|
| Stress, Mechanical | 5 | 2007 | 1660 | 0.070 |
Why?
|
| Educational Measurement | 1 | 2014 | 1244 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 1440 | 0.070 |
Why?
|
| Disease Progression | 8 | 2013 | 13403 | 0.070 |
Why?
|
| Iliac Artery | 2 | 2007 | 344 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 590 | 0.070 |
Why?
|
| Cohort Studies | 6 | 2015 | 40996 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 2093 | 0.070 |
Why?
|
| Endocarditis, Bacterial | 1 | 2011 | 446 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 1992 | 1342 | 0.070 |
Why?
|
| Survival Rate | 3 | 2023 | 12751 | 0.070 |
Why?
|
| Physical Therapy Modalities | 1 | 1991 | 532 | 0.070 |
Why?
|
| Forecasting | 1 | 2016 | 2917 | 0.070 |
Why?
|
| Hospitalization | 3 | 2024 | 10628 | 0.070 |
Why?
|
| Peptides, Cyclic | 3 | 2009 | 393 | 0.070 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2009 | 419 | 0.070 |
Why?
|
| Heart Conduction System | 1 | 2012 | 1014 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2011 | 1178 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 1988 | 433 | 0.070 |
Why?
|
| Triglycerides | 4 | 2003 | 2469 | 0.070 |
Why?
|
| Prosthesis-Related Infections | 1 | 2011 | 485 | 0.070 |
Why?
|
| Azetidines | 1 | 2007 | 136 | 0.070 |
Why?
|
| Tachycardia, Ventricular | 1 | 1995 | 1292 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1996 | 2242 | 0.070 |
Why?
|
| Preventive Medicine | 1 | 1987 | 252 | 0.060 |
Why?
|
| Phospholipids | 1 | 2009 | 786 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2010 | 15438 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 1 | 1991 | 745 | 0.060 |
Why?
|
| Patient Selection | 3 | 2012 | 4239 | 0.060 |
Why?
|
| Anaphylaxis | 1 | 2012 | 747 | 0.060 |
Why?
|
| Mass Screening | 3 | 1990 | 5395 | 0.060 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2010 | 612 | 0.060 |
Why?
|
| Pulmonary Veins | 1 | 2010 | 732 | 0.060 |
Why?
|
| Lipid Metabolism | 2 | 2005 | 1894 | 0.060 |
Why?
|
| Exercise Test | 3 | 2018 | 2114 | 0.060 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 3677 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 2264 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 14601 | 0.060 |
Why?
|
| Oxidative Stress | 3 | 2006 | 3051 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2007 | 823 | 0.060 |
Why?
|
| Incidence | 5 | 2013 | 21162 | 0.060 |
Why?
|
| Professional Review Organizations | 2 | 2012 | 49 | 0.050 |
Why?
|
| Solubility | 1 | 2004 | 1083 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2008 | 2635 | 0.050 |
Why?
|
| Echocardiography | 2 | 2011 | 4949 | 0.050 |
Why?
|
| omega-N-Methylarginine | 1 | 2001 | 108 | 0.050 |
Why?
|
| Compliance | 1 | 2001 | 100 | 0.050 |
Why?
|
| Animals | 9 | 2022 | 166825 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 7997 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2001 | 126 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 2 | 1998 | 1599 | 0.050 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2001 | 145 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 2088 | 0.050 |
Why?
|
| Apolipoproteins | 1 | 2003 | 319 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2011 | 6363 | 0.050 |
Why?
|
| Contrast Media | 2 | 2012 | 5276 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 1553 | 0.050 |
Why?
|
| Cardiovascular Surgical Procedures | 2 | 2012 | 192 | 0.050 |
Why?
|
| Total Quality Management | 2 | 2012 | 267 | 0.050 |
Why?
|
| Insulin | 1 | 2015 | 6566 | 0.050 |
Why?
|
| Blood Coagulation | 2 | 2024 | 1149 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 2119 | 0.050 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2024 | 859 | 0.040 |
Why?
|
| Heart Diseases | 2 | 1990 | 2790 | 0.040 |
Why?
|
| Kidney | 1 | 2015 | 6985 | 0.040 |
Why?
|
| ROC Curve | 1 | 2007 | 3533 | 0.040 |
Why?
|
| Troponin | 1 | 2003 | 516 | 0.040 |
Why?
|
| Elasticity | 1 | 2001 | 653 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2011 | 3803 | 0.040 |
Why?
|
| Terrorism | 1 | 2002 | 212 | 0.040 |
Why?
|
| Developing Countries | 2 | 2003 | 2820 | 0.040 |
Why?
|
| Inguinal Canal | 1 | 2019 | 72 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 1998 | 53 | 0.040 |
Why?
|
| Linear Models | 4 | 2013 | 5858 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 2037 | 0.040 |
Why?
|
| Autoantibodies | 2 | 2009 | 2076 | 0.040 |
Why?
|
| Pyridones | 1 | 2024 | 766 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1991 | 1634 | 0.040 |
Why?
|
| Health Behavior | 1 | 1990 | 2614 | 0.040 |
Why?
|
| Hypertension | 2 | 2012 | 8497 | 0.040 |
Why?
|
| Radiography | 1 | 2009 | 6964 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2002 | 657 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 909 | 0.040 |
Why?
|
| Massachusetts | 1 | 2011 | 8706 | 0.040 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2001 | 315 | 0.040 |
Why?
|
| Education, Medical, Undergraduate | 1 | 1987 | 1049 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2001 | 650 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2001 | 413 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2022 | 9174 | 0.040 |
Why?
|
| Consensus | 2 | 2017 | 3037 | 0.040 |
Why?
|
| Medicare | 1 | 2015 | 6689 | 0.040 |
Why?
|
| Ultrasonography | 4 | 2005 | 5918 | 0.040 |
Why?
|
| Wettability | 1 | 1996 | 24 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2010 | 2724 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2020 | 53833 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 1996 | 60 | 0.040 |
Why?
|
| Absorption | 1 | 1996 | 242 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8549 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1990 | 3117 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 10798 | 0.030 |
Why?
|
| Cost Allocation | 1 | 1996 | 50 | 0.030 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 7730 | 0.030 |
Why?
|
| Thrombectomy | 1 | 2001 | 694 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 2224 | 0.030 |
Why?
|
| Benchmarking | 2 | 2012 | 1036 | 0.030 |
Why?
|
| Ankle | 1 | 2019 | 349 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2001 | 821 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2013 | 694 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 1998 | 363 | 0.030 |
Why?
|
| Physician's Role | 1 | 2002 | 914 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 5280 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2011 | 1109 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 1996 | 196 | 0.030 |
Why?
|
| Cholestyramine Resin | 1 | 1994 | 25 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2022 | 1557 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1998 | 756 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2001 | 1341 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2001 | 1241 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2024 | 1988 | 0.030 |
Why?
|
| Rest | 1 | 2018 | 914 | 0.030 |
Why?
|
| Health Services | 1 | 1998 | 751 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 6791 | 0.030 |
Why?
|
| San Francisco | 1 | 2012 | 161 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 1380 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 1993 | 572 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 1998 | 829 | 0.030 |
Why?
|
| Prevalence | 2 | 2024 | 15505 | 0.030 |
Why?
|
| Neutropenia | 1 | 1997 | 884 | 0.030 |
Why?
|
| Ambulances | 1 | 2012 | 92 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2019 | 909 | 0.020 |
Why?
|
| Lipids | 3 | 2005 | 3325 | 0.020 |
Why?
|
| Observer Variation | 2 | 2013 | 2581 | 0.020 |
Why?
|
| Urban Health Services | 1 | 2012 | 176 | 0.020 |
Why?
|
| Drainage, Postural | 1 | 1991 | 2 | 0.020 |
Why?
|
| Percussion | 1 | 1991 | 18 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 2011 | 172 | 0.020 |
Why?
|
| Medication Therapy Management | 1 | 2012 | 130 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 3703 | 0.020 |
Why?
|
| Patient Care Team | 2 | 2012 | 2484 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 4286 | 0.020 |
Why?
|
| Suction | 1 | 2011 | 262 | 0.020 |
Why?
|
| Water | 1 | 1996 | 1395 | 0.020 |
Why?
|
| Heart Rate | 2 | 2003 | 4096 | 0.020 |
Why?
|
| Patient Admission | 1 | 1997 | 1375 | 0.020 |
Why?
|
| Education, Medical, Graduate | 2 | 2012 | 2321 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2012 | 955 | 0.020 |
Why?
|
| Fever | 1 | 1997 | 1613 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1991 | 616 | 0.020 |
Why?
|
| North America | 1 | 2013 | 1280 | 0.020 |
Why?
|
| Hemoptysis | 1 | 2010 | 152 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 3829 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2007 | 36038 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 3 | 2011 | 7294 | 0.020 |
Why?
|
| Community Health Nursing | 1 | 1988 | 23 | 0.020 |
Why?
|
| Peptides | 1 | 2001 | 4306 | 0.020 |
Why?
|
| Pneumonia | 1 | 2000 | 2122 | 0.020 |
Why?
|
| Photometry | 1 | 1988 | 55 | 0.020 |
Why?
|
| Reagent Strips | 1 | 1988 | 38 | 0.020 |
Why?
|
| Sputum | 1 | 1991 | 501 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2012 | 772 | 0.020 |
Why?
|
| Smoking | 3 | 2003 | 9029 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1994 | 1674 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1998 | 2680 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2009 | 21857 | 0.020 |
Why?
|
| Troponin I | 1 | 2012 | 632 | 0.020 |
Why?
|
| South Africa | 1 | 2013 | 1773 | 0.020 |
Why?
|
| Emergencies | 1 | 2013 | 1176 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2013 | 25540 | 0.020 |
Why?
|
| Hemorheology | 1 | 2007 | 144 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2012 | 1609 | 0.020 |
Why?
|
| Emergency Medical Services | 2 | 2012 | 1909 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2012 | 1436 | 0.020 |
Why?
|
| Cost of Illness | 1 | 1996 | 1911 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3407 | 0.020 |
Why?
|